Table 8.
Kinetics of immune responses post third dose by study vaccine and priming vaccine schedule among the modified intention-to-treat population of immunology cohort, group A
|
Prime with ChAd/ChAd |
Prime with BNT/BNT |
|||||||
|---|---|---|---|---|---|---|---|---|
| Control (n=18) | ChAd (n=16) | NVX (n=19) | NVX half (n=21) | Control (n=26) | ChAd (n=24) | NVX (n=24) | NVX half (n=21) | |
| SARS-CoV-2 anti-spike IgG, ELU/mL | ||||||||
| Day 0 | 1237 (835–1833; n=18) | 786 (593–1041; n=16) | 1053 (610–1818; n=19) | 1073 (702–1641; n=21) | 3482 (2482–4886; n=26) | 3196 (2142–4769; n=24) | 3512 (2454–5026; n=24) | 4469 (2836–7043; n=21) |
| Day 7 | 1177 (750–1849; n=14) | 1242 (942–1637; n=15) | 2935 (1932–4457; n=18) | 3543 (2521–4979; n=20) | 3124 (2216–4404; n=25) | 8624 (6664–11 160; n=24) | 5080 (3585–7199; n=23) | 4881 (3207–7428; n=20) |
| Day 28 | 841 (538–1313; n=16) | 1321 (995–1752; n=15) | 4791 (3390–6769; n=18) | 4959 (3413–7206; n=21) | 2415 (1751–3330; n=26) | 13 708 (10 368–18 125; n=24) | 8754 (6262–12236; n=24) | 10 171 (6892–15 010; n=21) |
| Cellular response (wild-type), spot forming cells per 106peripheral blood mononuclear cells | ||||||||
| Day 0 | 52·8 (34·4–81·0; n=18) | 61·7 (37·2–102·4; n=16) | 25·3 (13·9–46·0; n=19) | 37·1 (24·2–56·8; n=20) | 37·9 (23·8–60·5; n=25) | 57·9 (32·1–104·3; n=23) | 56·9 (35·2–91·9; n=23) | 25·8 (14·7–45·1; n=20) |
| Day 14 | 48·7 (24·1–98·3; n=14) | 91·1 (48·7–170·6; n=13) | 239·6 (156·0–368·0; n=18) | 133·0 (76·8–230·4; n=20) | 33·7 (20·2–56·1; n=25) | 134·9 (75·9–239·9; n=24) | 85·8 (52·4–140·7; n=23) | 69·5 (40·9–118·1; n=20) |
| Day 28 | 56·1 (30·6–103·1; n=16) | 72·4 (43·8–119·5; n=15) | 104·5 (59·2–184·3; n=17) | 171·5 (126·7–232·0; n=19) | 33·2 (20·8–53·0; n=25) | 116·4 (67·8–199·7; n=23) | 75·0 (40·6–138·4; n=23) | 39·8 (19·3–82·3; n=20) |
Data are geometric mean (95% CI; number of samples available). ChAd=ChAdOx1 nCoV-19 vaccine, Oxford–AstraZeneca. BNT=BNT162b2 vaccine, Pfizer–BioNTech. Control=quadrivalent meningococcal conjugate vaccine. NVX=NVX-CoV2373 vaccine, Novavax. NVX half=half dose of NVX-CoV2373 vaccine. ELU=ELISA laboratory units.